ID   LNCaP-CL1
AC   CVCL_3872
SY   CL1; CL-1
DR   BTO; BTO:0005673
DR   cancercelllines; CVCL_3872
DR   Wikidata; Q54902832
RX   PubMed=10992426;
RX   PubMed=11038142;
RX   PubMed=15162376;
RX   PubMed=15833837;
CC   Population: Caucasian.
CC   Characteristics: Androgen-independent. Has highly locally invasive and metastatic properties.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=10992426; DOI=10.1016/S0022-5347(05)67210-2;
RA   Patel B.J., Pantuck A.J., Zisman A., Tsui K.-H., Paik S.H.,
RA   Caliliw R., Sheriff S., Wu L., deKernion J.B., Tso C.-L.,
RA   Belldegrun A.S.;
RT   "CL1-GFP: an androgen independent metastatic tumor model for prostate
RT   cancer.";
RL   J. Urol. 164:1420-1425(2000).
//
RX   PubMed=11038142;
RA   Tso C.-L., McBride W.H., Sun J.-R., Patel B., Tsui K.-H., Paik S.H.,
RA   Gitlitz B., Caliliw R., van Ophoven A., Wu L., deKernion J.B.,
RA   Belldegrun A.S.;
RT   "Androgen deprivation induces selective outgrowth of aggressive
RT   hormone-refractory prostate cancer clones expressing distinct cellular
RT   and molecular properties not present in parental androgen-dependent
RT   cancer cells.";
RL   Cancer J. Sci. Am. 6:220-233(2000).
//
RX   PubMed=15162376; DOI=10.1002/pros.20031;
RA   Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M.,
RA   Vessella R.L., Belldegrun A.S., Hood L.E.;
RT   "Lineage relationship between LNCaP and LNCaP-derived prostate cancer
RT   cell lines.";
RL   Prostate 60:98-108(2004).
//
RX   PubMed=15833837; DOI=10.1158/0008-5472.CAN-04-3218;
RA   Lin B.-Y., White J.T., Lu W., Xie T., Utleg A.G., Yan X.-W., Yi E.C.,
RA   Shannon P., Khrebtukova I., Lange P.H., Goodlett D.R., Zhou D.-X.,
RA   Vasicek T.J., Hood L.E.;
RT   "Evidence for the presence of disease-perturbed networks in prostate
RT   cancer cells by genomic and proteomic analyses: a systems approach to
RT   disease.";
RL   Cancer Res. 65:3081-3091(2005).
//